Aripiprazol Kullan�m�na Ba�l� Nadir G�r�len �nterstisyel Pn�moni: Olgu Sunumu

Alpagat, G�listan; Bacc�o�lu, Ay�e; Yal�m, S�meyra Alan; Poyraz, Merve; Dumano�u, Bet�l; Kalpakl�o�lu, Ay�e F�sun

Cilt : 11 Say� : 1 Y�l : 2022

11/2Son Say� Erken Bask� Ar�iv Pop�ler Makaleler

Yay�n Hakk� Devir Formu

Yazar Katk� Formu

H�zl� Arama

Laparoscopic Endoscopic Surgical Science Aripiprazol Kullan�m�na Ba�l� Nadir G�r�len �nterstisyel Pn�moni: Olgu Sunumu [Respir Case Rep]

Respir Case Rep. 2022; 11(1): 44-49 | DOI: 10.5505/respircase.2022.80948

Aripiprazol Kullan�m�na Ba�l� Nadir G�r�len �nterstisyel Pn�moni: Olgu Sunumu

G�listan Alpagat, Ay�e Bacc�o�lu, S�meyra Alan Yal�m, Merve Poyraz, Bet�l Dumano�u, Ay�e F�sun Kalpakl�o�lu
K�r�kkale �niversitesi T�p Fak�ltesi, �mmunoloji ve Allerji Hastal�klar�, K�r�kkale

�nterstisyel akci�er hastal�klar�n�n (IAH) %2-3'unun ila�lara ba�l� oldu�u ve ilaca ba�l� akci�er hastal�klar�n�n %70'inin IAH'dan oldu�u kabul edilmektedir. Elli bir ya��nda kad�n hasta 3 y�ld�r bipolar bozukluk i�in aripiprazol kullanmakta ve 2 y�ld�r ast�m tedavisi g�rmekteydi. Hastan�n klini�i, solunum fonksiyon testinde (SFT) restriktif patern olmas�, azalm�� karbon monoksit dif�zyon testi, laboratuvar sonu�lar�, radyolojik bulgular� ve biyopsi ile IAH d��n�ld�. Olas� etiyolojiler: enfeksiyon, aspirasyon, kalp yetmezli�i, evcil hayvan besleme durumu, tehlikeli solunum maddelerine maruziyet d��land�. ��pheli ila� kesilerek, oral kortikosteroid tedavisi ba�land�. �la� tedavileri ile akci�er toksisitesi geli�ebilir. �la� �yk�s� ayr�nt�l� olarak sorgulanmal� ve ��phe durumunda derhal kesilmelidir. IAH nadir g�r�l�r; ila�tan ��phelenilmez de devam edilirse hastal�k kronikle�ebilir ve solunum yetmezli�ine ilerleyebilir. Hastal�kla ilgili fark�ndal�� art�rmak i�in bu olguyu sunmaya ama�lad�k.

Anahtar Kelimeler: �nterstisyel Akci�er Hastal��, aripiprazol, interstisyel pn�moni, steroid tedavi

Rare Interstitial Pneumonia Due to the Use of Aripiprazol: A Case Report

G�listan Alpagat, Ay�e Bacc�o�lu, S�meyra Alan Yal�m, Merve Poyraz, Bet�l Dumano�u, Ay�e F�sun Kalpakl�o�lu
Department of Immunology and Allergy Disease, K�r�kkale University Faculty of Medicine, K�r�kkale, Turkey

It is accepted that 2�3% of interstitial lung diseases (ILD) are due to drugs, and that 70% of drug-induced lung diseases are due to ILD. We present here the case of a 51-year-old female patient who had been taking aripiprazole for bipolar disorder for 3 years and had been undergoing asthma treatment for 2 years. ILD was considered based on the patient's clinic, a restrictive pattern in the pulmonary function test (PFT), a decreased carbon monoxide diffusion test, laboratory results, radiological findings and biopsy. The possible etiologies of infection, aspiration, heart failure, pet feeding status and exposure to hazardous respiratory substances were excluded. The suspected drug was discontinued and oral corticosteroid treatment was started. Lung toxicity can develop with drug treatments, and so drug history should be questioned in detail and discontinued immediately in case of any doubt. ILD is rare, and if the drug is not suspected and continued, the disease may become chronic and progress to respiratory failure. We present this case to increase awareness of the disease.

Keywords: Interstitial Lung Disease, aripiprazole, interstitial pneumonitis, steroid treatment

Olgunun G�r�nt� Kesitleri

G�listan Alpagat, Ay�e Bacc�o�lu, S�meyra Alan Yal�m, Merve Poyraz, Bet�l Dumano�u, Ay�e F�sun Kalpakl�o�lu. Rare Interstitial Pneumonia Due to the Use of Aripiprazol: A Case Report. Respir Case Rep. 2022; 11(1): 44-49

Sorumlu Yazar: G�listan Alpagat, T�rkiye
Makale Dili: �ngilizce

ARA�LAR Tam Metin PDF Yazd�r Al�nt�y� �ndir RIS EndNote BibTex Medlars Procite Reference Manager E-Postala Payla� Yazara e-posta g�nder Benzer makaleler PubMed Google Scholar